Stemson Therapeutics Announces Technological Breakthrough in new Hair Growth 2/6/2024
Stemson Therapeutics announced a breakthrough in hair growth technology using stem cells. Users discussed the potential high cost and skepticism about the treatment's accessibility.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Stem-cell hair transplants! 20k lab grown grafts from one single graft
Stem-cell hair transplants could potentially create thousands of grafts from a single donor graft, offering a solution for hair loss with DHT-resistant hair. Companies like Stemson Therapeutics and OrganTech are working on this technology, which may become available in the future, possibly reducing the cost and making it widely accessible.
community How soon is hair clone? Next five years?!
Hair cloning is humorously discussed as always being 5-7 years away, with skepticism about its near-term availability. Gene editing to reactivate dormant follicles is suggested as a more likely solution within the next ten years.
community Say this new supposed miracle drug “PP405” does actually cure baldness, how will that affect people with hair transplants?
PP405 may reactivate dormant hair follicles but won't replace hair transplants or resurrect dead follicles. Its effectiveness, cost, and impact compared to treatments like minoxidil and finasteride are uncertain.
community I think we should all keep an eye out for Pelage PP405. February 2025 will be interesting.
Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.
community The Chinese version of Stemson Therapeutics (Hair Multiplication) is here. It is called Yunce Medical.
Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.
Related Research
6 / 6 results
research Clinical translational research on stem cell products: prospects and challenges
This review highlights the promising role of stem cell therapy in treating resistant diseases, while also addressing the challenges in production and clinical application, emphasizing the need for standardized manufacturing and quality assurance to enhance efficacy and safety in clinical translational research.
research An induced pluripotent stem cell-based approach for hair follicle development and regeneration
This review discussed the potential of induced pluripotent stem cells (iPSCs) for hair follicle regeneration, covering current approaches and challenges, iPSC differentiation, and their possible future clinical applications in hair restoration.
research The origins of skin diversity: lessons from dermal fibroblasts
This review discusses the developmental origins and diversity of dermal fibroblasts, focusing on their roles in epidermal and hair follicle growth, but reports no clinical results.
research Applications of Human Pluripotent Stem Cell–Derived Skin Organoids in Dermatology
This study provided an overview of skin organoids created from pluripotent stem cells, showcasing their potential in dermatologic research and future clinical applications, while noting challenges such as lengthy differentiation protocols that result in heterogeneous products.
research Regenerative Strategies for Androgenetic Alopecia: Evidence, Mechanisms, and Translational Pathways
This study highlights emerging regenerative strategies, such as stem cell-derived therapies and machine learning tools, that may advance hair loss treatment beyond traditional methods by promoting follicle regeneration and offering personalized care.
research Tunable Keratin Hydrogels for Controlled Erosion and Growth Factor Delivery
This study describes a method to create keratin hydrogels with adjustable erosion rates by mixing different ratios of keratose and kerateine, enabling controlled release of therapeutic agents like insulin-like growth factor 1.